carteolol has been researched along with Myocardial Ischemia in 2 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of carteolol, which is a nonselective beta-adrenergic agent with intrinsic sympathomimetic activity, on silent myocardial ischemia, exercise-induced myocardial ischemia, indexes of heart rate variability, and pain-modulating system, 20 patients (mean 60 +/- 9 years) with chronic stable angina underwent exercise treadmill testing and 24-hour ambulatory electrocardiographic monitoring during 2 weeks of carteolol administration (15 mg/day) in a double-blind, placebo-controlled design." | 9.08 | Effect of carteolol on silent myocardial ischemia, variability in heart rate, and the pain-modulating system. ( Hikita, H; Kurita, A; Nakamura, H; Satomura, K; Takase, B; Uehata, A, 1997) |
| "To investigate the effects of carteolol, which is a nonselective beta-adrenergic agent with intrinsic sympathomimetic activity, on silent myocardial ischemia, exercise-induced myocardial ischemia, indexes of heart rate variability, and pain-modulating system, 20 patients (mean 60 +/- 9 years) with chronic stable angina underwent exercise treadmill testing and 24-hour ambulatory electrocardiographic monitoring during 2 weeks of carteolol administration (15 mg/day) in a double-blind, placebo-controlled design." | 5.08 | Effect of carteolol on silent myocardial ischemia, variability in heart rate, and the pain-modulating system. ( Hikita, H; Kurita, A; Nakamura, H; Satomura, K; Takase, B; Uehata, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rump, AF | 1 |
| Picke, D | 1 |
| Rösen, R | 1 |
| Klaus, W | 1 |
| Takase, B | 1 |
| Hikita, H | 1 |
| Uehata, A | 1 |
| Satomura, K | 1 |
| Kurita, A | 1 |
| Nakamura, H | 1 |
1 trial available for carteolol and Myocardial Ischemia
| Article | Year |
|---|---|
Effect of carteolol on silent myocardial ischemia, variability in heart rate, and the pain-modulating system.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; beta-Endorphin; Bradykinin; Carteolol; | 1997 |
1 other study available for carteolol and Myocardial Ischemia
| Article | Year |
|---|---|
Effects of propranolol, pindolol and carteolol on acute regional myocardial ischemia in isolated rabbit hearts.
Topics: Adrenergic beta-Antagonists; Animals; Carteolol; Catecholamines; Coronary Circulation; Electric Stim | 1993 |